No abstract

Aim: to describe clinical characteristics of women with endometrial hyperplasia. Patients and Methods: this retrospective single-center study enrolled 86 women who underwent hysteroscopic curettage (with subsequent histology) on the basis of complaints and ultrasound. All women were divided into three groups. Group 1 included 30 women with endometrial hyperplasia (EH). Group 2 included 30 women with endometrial polyps (EP). Group 3 included 26 healthy women without any endometrium conditions (control group). Somatic status, obstetric gynecologic anamnesis, and comorbidities were evaluated. Results: in women with EH, heavy periods were 2.37- and 2.6-times more common than in groups 2 and 3 (p<0.05) while the rate of other abnormal uterine bleedings was 7.06- and 6.06-times higher, respectively (p<0.05). In women with EH, anemia was diagnosed 4- and 5.2-times more common than in groups 2 (p<0.05) and 3 (p<0.05), respectively. In group 2, inflammatory cervical and vaginal conditions were 3.98- and 3.46-times more common than in group 1 (p<0.05) and group 3 (p>0.05). The occurrence of endocrine disorders in group 1 was 4.49- and 3.9-times higher than in group 2 and 3, respectively (p<0.05). Anamnestic thrombosis, strokes, and migraines were reported only in women with EH. Conclusions: prevention of endometrium conditions entails both early detection and control over ovulation and management of endocrine disorders and treatment of genital tract inflammation. When managing women with uterine fibroids and adenomyosis and anamnestic thrombosis, a doctor should be vigilant about EH. KEYWORDS: endometrial hyperplasia, endometrial polyp, inflammation, hyperplastic conditions, uterus, thrombosis. FOR CITATION: Salamova K.K., Saprykina L.V., Ramazanova A.M. et al. Clinical characteristics of women with endometrial hyperplasia. Russian Journal of Woman and Child Health. 2021;4(2):124–129. DOI: 10.32364/2618-8430-2021-4-2-124-129.

Introduction. Amidst a steady increase in hyperplastic processes in uterus and mammary glands, numerous studies have shown that women with dyshormonal pathology of mammary glands had a range of gynecological diseases: external or internal endometriosis, hyperplastic processes of the endometrium and myometrium, polyps, polycystic ovary syndrome (PCOS), etc.Objective. To assess the mammary gland condition in premenopausal women with endometrial hyperplasia during indole-3-car-binol (I3C) therapy.Materials and methods. A total of 42 premenopausal patients aged 45-52 years (48.54 ± 1.83) were enrolled in an open-label prospective study. All patients received I3C 400 mg a day for 12 months. The examination included clinical laboratory, ultrasound imaging and mammographic examination of the mammary glands, cytologic examination of a nipple discharge. The examinations were carried out at the baseline, 6 and 12 months after starting treatment. The study findings were evaluated using descriptive statistics. Differences were considered significant at p <0.05.Results and discussion. All patients were diagnosed as having mastalgia before starting treatment. Mammary gland ultrasound imaging showed that the frequency of BI-RADS 2 was 9.5 times higher than that of BI-RADS 1 (90.5% and 9.5%, respectively, p <0.05). Mammography revealed that the frequency of BI-RADS 2 was 9.26 times higher than that of BI-RADS 1 (88% and 9.5%, respectively, p <0.05). After 6-month therapy, 59.5% of patients reported the disappearance of pain syndrome, the number of patients with ONE1/16a-ONE1 deviations decreased by 22%, 7.1% of patients showed improvement of ultrasound picture in BI-RADS. After 12-month therapy, the number of patients with ONE1 / 16a-ONE1 deviations decreased by 92.86% compared with the figures before starting treatment, ultrasound imaging showed improvement in the BI-RADS picture in 19% of patients, mammography findings - in 28.5% of patients. I3C is an effective and safe method to treat benign breast diseases in premenopausal women.Conclusion. Indole-3-carbinol therapy can be assessed as the treatment having an influence on the general components of pathogenesis of endometrial hyperplasia and benign hyperplastic processes in mammary glands. It is advisable to consider the use of indole-3-carbinol combined with antioxidant resveratrol in clinical practice.

Despite the proven effect of menopausal hormone therapy on menopausal syndrome, a number of factors prevent perimenopausal women from receiving the treatment. The article is a review of literature on the possibility of non-hormonal treatment with tofisopam for neuro-vegetative and psycho-emotional disorders associated with climacteric syndrome. The article tells about the efficacy and safety of the drug taking into account its pharmacodynamic properties.

More than 600 thousands abortions are performed annually in Russia. Women presenting for abortion care are often motivated by the pregnancy to use effective contraception; they are also at high risk for repeat unintended pregnancy. Contraceptive counseling and the supply of contraceptive methods are part of post-abortion care and positively influence the subsequent use of contraceptive methods. Oral contraceptives (OCs) following induced abortion offer a reliable method to avoid repeated abortion. Immediate administration of combined OCs after abortion may reduce vaginal bleeding time and amount, shorten the menstruation recovery period, and reduce the risk of complications and unintended pregnancies. Сombination of ethinylestradiol 30 g + drospirenone 3 mg demonstrates the advantages of a low estrogen dose with the antimineralocorticoid activity of drospirenone that is responsible for the drugs significant antiandrogenic and antimineralocorticoid effects, reflected clinically in lower rates of adverse events including less fluid retention. Сombination of ethinylestradiol 30 g + drospirenone 3 mg and Metafolin has similar contraceptive efficacy, side effect, safety and benefits profile to other drospirenone-containing contraceptives. The article presents the results of the latest studies about using of combined OCs (ethinylestradiol 30 g + drosperinone 3 mg and Metafolin) after abortion.